{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:53:08Z","timestamp":1785275588984,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010677","name":"H2020 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaut.2019.102316","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T10:34:49Z","timestamp":1566038089000},"page":"102316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Predictive markers of lymphomagenesis in Sj\u00f6gren's syndrome: From clinical data to molecular stratification"],"prefix":"10.1016","volume":"104","author":[{"given":"Efstathia K.","family":"Kapsogeorgou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Voulgarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.102316_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102316_bib2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.autrev.2012.11.004","article-title":"Lymphocyte transformation and autoimmune disorders","volume":"12","author":"Tarella","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102316_bib4","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102316_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","article-title":"Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study","volume":"50","author":"Theander","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients","volume":"75","author":"Brito-Zeron","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kem079","article-title":"Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors","volume":"46","author":"Brito-Zeron","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sjogren's syndrome: predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102316_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2015.03.004","article-title":"Clinical picture, outcome and predictive factors of lymphoma in Sjgren syndrome","volume":"14","author":"Papageorgiou","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102316_bib13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0961203319857132","article-title":"Prognostic markers of lymphoma development in primary Sjogren syndrome","volume":"28","author":"Retamozo","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102316_bib14","first-page":"888","article-title":"Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjogren's syndrome","volume":"23","author":"Saito","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ajcp\/92.3.357","article-title":"Sjogren's syndrome with specific cutaneous manifestations and multifocal clonal T-cell populations progressing to a cutaneous pleomorphic T-cell lymphoma","volume":"92","author":"van der Valk","year":"1989","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.jaut.2019.102316_bib16","first-page":"428","article-title":"[Non-Hodgkin's malignant T-cell lymphoma in Gougerot-Sjogren syndrome]","volume":"140","author":"Fredenrich","year":"1989","journal-title":"Ann. Med. Interne"},{"key":"10.1016\/j.jaut.2019.102316_bib17","first-page":"117","article-title":"[Angiocentric pulmonary T-cell lymphoma associated with primary Sjogren syndrome]","volume":"107","author":"Ros","year":"1996","journal-title":"Med. Cl\u00ednica"},{"key":"10.1016\/j.jaut.2019.102316_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1346-8138.2002.tb00244.x","article-title":"Lymphomatoid papulosis associated with Sjogren's syndrome","volume":"29","author":"Yamamoto","year":"2002","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2019.102316_bib19","first-page":"1744","article-title":"Peripheral T cell lymphoma with Sjogren's syndrome: a report with immunologic and genotypic studies","volume":"18","author":"Chevalier","year":"1991","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/art.1780270818","article-title":"T cell lymphoma occurring in Sjogren's syndrome","volume":"27","author":"Wilke","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib22","first-page":"1548","article-title":"Angiocentric T cell lymphoma of the central nervous system in a patient with Sjogren's syndrome","volume":"29","author":"Khanna","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.reuma.2013.12.005","article-title":"Hepatosplenic gammadelta T-cell lymphoma and Sjogren's syndrome","volume":"10","author":"Godinho","year":"2014","journal-title":"Reumatol. Cl\u00ednica"},{"key":"10.1016\/j.jaut.2019.102316_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116189","article-title":"Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients","volume":"10","author":"Papageorgiou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102316_bib25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jaut.2019.102316_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine"},{"key":"10.1016\/j.jaut.2019.102316_bib27","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102316_bib28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102316_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.jaut.2019.102316_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sjogren syndrome","volume":"10","author":"Brito-Zeron","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jaut.2019.102316_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib32","first-page":"1860","article-title":"Report of the committee on hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.jaut.2019.102316_bib33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102316_bib35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/rheumatology\/key392","article-title":"Is early-onset primary Sjogren's syndrome a worse prognosis form of the disease?","volume":"58","author":"Anquetil","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib36","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sjogren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by Autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1191\/096120398678920019","article-title":"Young onset of primary Sjogren's syndrome: clinical and immunological characteristics","volume":"7","author":"Ramos-Casals","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102316_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/03009749950155599","article-title":"The influence of age on disease manifestations and serological characteristics in primary Sjogren's syndrome","volume":"28","author":"Haga","year":"1999","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib39","first-page":"795","article-title":"Clinical and immunological characteristics of elderly onset Sjogren's syndrome: a comparison with younger onset disease","volume":"28","author":"Tishler","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/annrheumdis-2019-eular.7105","article-title":"Analysis of clinical and serological picture of patients with primary Sj\u00f6gren\u2019s syndrome and an early disease onset at age before 35 years","volume":"78","author":"Argyropoulou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-eular.6990","article-title":"Comparison of clinical phenotype, serological characteristics and histologic features of males vs females patients with primary Sj\u00f6gren\u2019s syndrome (pSS)","volume":"78","author":"Chatzis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/03009740802001426","article-title":"Primary Sjogren's syndrome in men","volume":"37","author":"Gondran","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13293-017-0146-6","article-title":"Long-term follow-up in primary Sjogren's syndrome reveals differences in clinical presentation between female and male patients","volume":"8","author":"Ramirez Sepulveda","year":"2017","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.jaut.2019.102316_bib44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/ard.54.9.748","article-title":"Primary Sjogren's syndrome in men","volume":"54","author":"Anaya","year":"1995","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.25680","article-title":"Non-Hodgkin lymphoma and autoimmunity: does gender matter?","volume":"129","author":"Ansell","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jaut.2019.102316_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/art.40528","article-title":"Ectopic germinal center-like structures in minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sjogren's syndrome","volume":"70","author":"Sene","year":"2018","journal-title":"Arthritis & rheumatology"},{"issue":"Suppl 112","key":"10.1016\/j.jaut.2019.102316_bib47","first-page":"121","article-title":"Severe, life-threatening phenotype of primary Sjogren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)","volume":"36","author":"Flores-Chavez","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl 112","key":"10.1016\/j.jaut.2019.102316_bib48","first-page":"150","article-title":"The evaluation of disease activity in Sjogren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study","volume":"36","author":"De Vita","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0049-0172(98)80040-1","article-title":"Predictors of lymphoma development in primary Sjogren's syndrome","volume":"28","author":"Sutcliffe","year":"1998","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semarthrit.2013.03.001","article-title":"Clinical features distinguishing lymphoma development in primary Sjogren's Syndrome--a retrospective cohort study","volume":"43","author":"Risselada","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jaut.2019.102316_bib52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2017-212639","article-title":"Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjogren's syndrome","volume":"77","author":"Kapsogeorgou","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","article-title":"Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study","volume":"51","author":"Quartuccio","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102316_bib54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3899\/jrheum.110754","article-title":"A clinical prediction rule for lymphoma development in primary Sjogren's syndrome","volume":"39","author":"Baldini","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2019.102316_bib56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome","volume":"41","author":"Solans-Laque","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","article-title":"A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience","volume":"14","author":"Abrol","year":"2014","journal-title":"Clin. Med."},{"key":"10.1016\/j.jaut.2019.102316_bib58","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2019.102316_bib59","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study","volume":"38","author":"Pollard","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib61","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/art.1780290907","article-title":"Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjogren's syndrome","volume":"29","author":"Tzioufas","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib62","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.49.11.929","article-title":"Association of serum IgM kappa monoclonicity in patients with Sjogren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands","volume":"49","author":"Moutsopoulos","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib63","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","article-title":"Anti-SSA\/SSB-negative Sjogren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution","volume":"14","author":"Quartuccio","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102316_bib64","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/art.39534","article-title":"Brief report: monoclonal gammopathy and risk of lymphoma and Multiple myeloma in patients with primary Sjogren's syndrome","volume":"68","author":"Tomi","year":"2016","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102316_bib66","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.39315","article-title":"CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjogren's syndrome","volume":"67","author":"Nocturne","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib68","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1002\/art.38129","article-title":"Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome","volume":"65","author":"Tobon","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102316_bib69","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/art.39231","article-title":"A BAFF receptor His159Tyr mutation in Sjogren's syndrome-related lymphoproliferation","volume":"67","author":"Papageorgiou","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2018.02.010","article-title":"Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren's syndrome fueled by inflammagenic DNA accumulations","volume":"91","author":"Vakrakou","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102316_bib71","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2019-eular.5758","article-title":"The role of the phospholipase LP-PLA2 activity in Sj\u00f6gren\u2019s syndrome related lymphomagenesis: a new serum biomarker?","volume":"78","author":"Kotsifaki","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaut.2012.05.018","article-title":"Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome","volume":"39","author":"Agmon-Levin","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102316_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2019-eular.5514","article-title":"Serum thymic stromal lymphopoietin (TSLP) as a biomarker of B-cell lymphoproliferation in Sj\u00f6gren\u2019s syndrome","volume":"78","author":"Gandolfo","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/36.9.969","article-title":"Quantitative assessment of salivary gland inflammatory infiltration in primary Sjogren's syndrome: its relationship to different demographic, clinical and serological features of the disorder","volume":"36","author":"Gerli","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0714.1997.tb00243.x","article-title":"An association between salivary gland disease and serological abnormalities in Sjogren's syndrome","volume":"26","author":"Nakamura","year":"1997","journal-title":"J. Oral Pathol. Med. : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"},{"key":"10.1016\/j.jaut.2019.102316_bib76","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sjogren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib78","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3899\/jrheum.131527","article-title":"Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjogren syndrome with and without lymphoma","volume":"41","author":"Johnsen","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib79","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102316_bib80","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.130256","article-title":"Minor salivary gland inflammatory lesions in Sjogren syndrome: do they evolve?","volume":"40","author":"Kapsogeorgou","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102316_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102316_bib82","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2019.102316_bib83","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon Pathways in Sjogren's syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102316_bib84","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.18632\/oncotarget.3052","article-title":"The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy","volume":"6","author":"Humphries","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaut.2019.102316_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1515\/bmc-2016-0020","article-title":"The microRNA-200 family: still much to discover","volume":"7","author":"Senfter","year":"2016","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.jaut.2019.102316_bib86","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00109-010-0643-0","article-title":"MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis","volume":"88","author":"Ragusa","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jaut.2019.102316_bib87","article-title":"Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102316_bib88","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3892\/mmr.2014.2366","article-title":"Transforming growth factorbeta1 induces epithelialmesenchymal transition and increased expression of matrix metalloproteinase16 via miR200b downregulation in bladder cancer cells","volume":"10","author":"Chen","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jaut.2019.102316_bib89","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3892\/mmr.2016.4933","article-title":"MicroRNA-200b inhibits epithelial-mesenchymal transition and migration of cervical cancer cells by directly targeting RhoE","volume":"13","author":"Cheng","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jaut.2019.102316_bib90","doi-asserted-by":"crossref","first-page":"16638","DOI":"10.18632\/oncotarget.3184","article-title":"Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer","volume":"6","author":"Rhodes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaut.2019.102316_bib91","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/annrheumdis-2019-eular.5561","article-title":"Predictive value of mir200b-5p in the lymphomagenesis in Sj\u00f6gren\u2019s syndrome (SS): comparison with the published prediction models. Preliminary results","volume":"78","author":"Kapsogeorgou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102316_bib92","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:24:58Z","timestamp":1760257498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119305116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":92,"alternative-id":["S0896841119305116"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102316","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive markers of lymphomagenesis in Sj\u00f6gren's syndrome: From clinical data to molecular stratification","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102316"}}